Navigation Links
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Date:3/25/2009

- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales -

- Company to Host Conference Call at 11:00 a.m. ET Today -

EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, today announced that it has entered into an agreement with Galderma S.A. to develop and commercialize NovaBay's novel proprietary Aganocide(R) compounds. The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis (nail fungus) and orphan drug indications.

Under the terms of the agreement, NovaBay expects to receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and future royalties on net sales of products. The agreement also envisages further cooperation for additional dermatological products and indications. Under the agreement, NovaBay will also receive escalating double-digit royalties on net sales of products.

Galderma will be responsible for the development costs of the acne and other indications, except in Japan, and for the ongoing development program for impetigo, upon the achievement of a specified milestone. Galderma will also reimburse NovaBay for the use of its personnel in support of the collaboration. NovaBay retains the right to co-market products resulting from the agreement in Japan. In addition, NovaBay has retained all rights in other Asian markets outside Japan, and has exclusive rights to promote the products developed under the agreement in the hos
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
2. Galderma Completes Acquisition of CollaGenex
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)... The Vanuatu National Advisory Committee on ... Communication (SNC) Project in collaboration with...ms Ltd. of New Zealand have generated preliminary ...l form the background for the country’s SNC ...on on Climate Change (UNFCCC). , ...
(Date:11/26/2009)...E, Ind. - A new generation of ultrasmall transisto...uctures called semiconducting nanowires are closer...t IBM, Purdue University and the University of Cal...earned how to create nanowires with layers of diff...omic level, which is a critical requirement for ma...
(Date:11/25/2009)... , ,, BOCA RATON, Fla., Nov. 25 /PRNe...inful year. Not so for BodyLogicMD. The nation,s ...icians specializing exclusively in medically super...r of physicians in its network since Novembe...gress to add more physician-owned centers, includi...
(Date:11/25/2009)...EGO, Nov. 25 Ardea Biosc... Barry D. Quart, Pharm.D., president and chief exe...21st Annual Health Care Conference. , ,Presentati...ual Health Care Conference,Date: Tuesday, Dec...cation: The New York Palace Hotel, New York, NY,W...
Breaking Biology Technology:Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...6 Today Top Institute,Pharma announces a highly p...elopment of a malaria vaccine. This TI Pharma proj...m previous studies. The project aims to,develop a ...the lives of,millions of people in developing coun... vaccine is currently commercially available, desp...
...nsing, Inc.,("Start"), a joint venture of Geron Co...rts the final risk assessment released by the US F...essment concluded that meat and,dairy products fro...uman,consumption., "FDA,s conclusion is consisten...uropean Food Safety Authority and studies in other...
... Training and Preparing for the NFL, Combine Use ...ST Sports Clubs(TM),...nologies Inc., wholly-owned subsidiary of Millenni...: MBTG), announced today that SURGEX(TM) is,curren...program provided to,elite Division I & II Collegia...
Other Biology Technology:Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 2Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 3Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers 4Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 2Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 3Pro Football Prospects Training at TEST Sports Clubs(TM) Use SURGEX(TM) as Part of Their Pre-Combine Training Regime 4
(Date:11/24/2009)...in that may help gut bacteria bind to the gastroin...otic producers to identify strains that are likely...eed to interact with cells lining the gut to have ...s in the gut they are more likely to stick around ...alie Juge from the Institute of Food Research. IF...
(Date:11/24/2009)... Medical Toxicology (ACMT) have signed an agreemen...l of Medical Toxicology (JMT), the official journ...reviously published by the University of Pennsylva... , an international, peer-reviewed journal, is ded...dical toxicology. The quarterly journal focuses o...
(Date:11/24/2009)...ter of debate. A high-profile study a few years ag...ir carbon from trees and leaves, evidence for a ve...ecosystems. , But new research from the Universi...ue. Algae provide a much richer diet for fish and ...d this week in the Proceedings of the National Ac...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 1ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 2ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis 4905 3Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 1Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 2Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 3Trident 28R 29 Raises Awareness and Funds for Childrens Oral Health Cause During the First Week of September 55485 4Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 1Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 2Spinal Implant Developed by Sanford Clinic Neurosurgeon Receives FDA 510 28k 29 Market Clearance as a Lumbar Intervertebral Body Fusion Device 55484 3
...ant form of tuberculosis (TB) has been linked to H... by researchers at Yale School of Medicine. , Publ...tudy is the result of a five-year collaboration be... who aim to integrate HIV and TB care and treatmen...llness in those with HIV infection in sub-Saharan ...
...g in your garden could be frighteningly large if o... the air, a new study concludes. The study adds su...rger during the late Paleozoic period because they... lead author Alexander Kaiser. , The study, "No gi...its beetle size, will be presented Oct. 10 and 1...
... known primarily for regulating sugar levels in th...fornia, Riverside, recently found that applying in...ed the healing process. , Skin wounds in rats trea...ells in the epidermis covered the wound more quick... skin, were faster in rebuilding blood vessels. ,...
Other Biology News:HIV/AIDS linked to extensively drug resistant TB 2Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3From managing sugar to managing healing 2
Mouse Anti-Human ENTPD5 Monoclonal Antibody, Unconjugated, Clone 4A5 from Abnova Corporation
Protein Staining Solution from Abnova Corporation
Mouse Anti-Human PASK Monoclonal Antibody, Unconjugated, Clone 6D10 from Abnova Corporation
Mouse Anti-Human CRKRS Monoclonal Antibody, Unconjugated, Clone 3C1 from Abnova Corporation
Biology Products: